Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the top stocks for an early retirement portfolio. On June 12, Cantor Fitzgerald maintained its price target of $55 and its rating of Neutral for Bristol-Myers Squibb Company (NYSE:BMY).

The company’s Cobenfy’s ADEPT-2 top-line data in Alzheimer’s Disease Psychosis is anticipated in 2025, possibly as early as the second half of that year. According to Cantor Fitzgerald, this information reflects “the highest-impact remaining catalyst for BMY shares this year.”

Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst

Pixabay/Public Domain

Cantor believes that Cobenfy will surpass Opdivo and Reblozyl as the company’s third-largest-selling medicine by 2030, making the treatment crucial to Bristol-Myers’ future revenue profile.

Despite its potential significance, Cantor Fitzgerald characterized ADEPT-2 as “challenging to handicap” because of the varied older group being treated, the lack of clinical data, and the substantial heterogenous in neuropsychiatric investigations.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that discovers, produces, and supplies prescription medications for severe illnesses in fields including cancer, hematology, immunology, cardiovascular disease, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.